Hormone Therapy and Risk of Breast Cancer: Where Are We Now?

John P. Micha1, Mark A. Rettenmaier1, Randy D. Bohart2, Bram H. Goldstein1

1Women’s Cancer Research Foundation, Laguna Beach, CA, USA, 2Oso Home Care, Inc., Irvine, CA, USA

Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. Hence, physicians and nurses should actively engage in constructive discourse with their patients regarding HRT while specifically reviewing the potential risks of its extended use as well as provide the available medical alternatives the patients could potentially use.

Key Words: Breast cancer, Estrogen, Hormone replacement therapy, Progestin

INTRODUCTION

Breast cancer is the most common female malignancy in the United States, afflicting 281,500 women in 2020 [1]. Fortunately, nearly two-thirds of breast cancer patient cases are diagnosed at a localized stage, wherein the 5-year survival rate is favorable. Age (45 to 75 years) is a primary risk factor for breast cancer development [2], in addition to ovarian hormones, the presence of BRCA1 (BReast CAncer gene 1) and BRCA2 (BReast CAncer gene 2) gene mutations, reproductive history, and previous chest irradiation [3,4].

HORMONE THERAPY AND BREAST CANCER

Since the 1970’s, approximately 600 million women from western countries have used hormone replacement therapy (HRT) [5]. HRT, encompassing conjugated estrogens alone, or in combination with progestin, is indicated to attenuate vasomotor symptoms, forestall cognitive deficits, and avert cardiovascular disease [6,7]. However, several randomized clinical trials and observational studies have impugned the safety of HRT because of the medication’s putative relationship with breast cancer incidence and mortality [5,8-10].

Estradiol heightens the risk of breast cancer in postmenopausal women and preclinical studies have demonstrated that progestin engenders progenitor cells in both human and breast cancer cells [11-13]. While estrogen and progesterone levels significantly decline following menopause, HRT-induced blood estrogen levels correlate with an increased incidence of estrogen receptor-positive breast cancer, especially in women with a higher body mass index [13]. Studies have remarked that perhaps, estrogen-alone is safe, whereas estrogen/progestin ostensibly accords a countervailing or detrimental effect [14,15]. Hence, when evaluating a woman’s lifetime risk for developing breast cancer, one should consider the persistent inclusion of these two agents, either independently or collectively.

WOMEN’S HEALTH INITIATIVE (WHI) AND MILLION WOMEN TRIALS

The WHI initially reported on the controversial ben-
efits and potential complications inherent in HRT in their 2002 landmark study [10]. The trial comprised 16,608 healthy postmenopausal women with a uterus who underwent treatment with conjugated equine estrogens (0.625 mg/d) and medroxyprogesterone acetate (2.5 mg/d) or placebo for a median duration of 7.2 years. The HRT group was associated with more breast cancer-related deaths compared to the placebo group (2.6 vs. 1.3 per 10,000 women annually), resulting in clinical trial termination. In 2004, the WHI evaluated 10,739 postmenopausal women with a prior hysterectomy, ages 50–79 years, who underwent either conjugated equine estrogens (0.625 mg/d) or placebo. This study was also prematurely closed due to the elevated risk of stroke in the HRT group although interestingly, the results suggested a possible decreased incidence in breast cancer [8].

In the Million Women Study, 1,084,110 women from the United Kingdom (U.K.), ages 50–64 years, reported their use of HRT (estrogen alone or progestin-estrogen) and were surveilled to ascertain the subjects’ breast cancer incidence and mortality [9]. The results suggested that women who underwent estrogen-only or estrogen-progestogen had a 1.3-fold risk or 2-fold risk of developing breast cancer, respectively. Following the results from the WHI and U.K. trials, the use of HRT declined significantly [16]; and from 2001 to 2004, an 8.6% decrease in breast cancer incidence was reported for women, 50 years or older [17].

WHI FOLLOW-UP STUDIES

Manson et al. [18] reported on the updated findings from the two WHI studies, indicating that hormone therapy may be beneficial in terms of all-cause mortality, with fewer risks (e.g., coronary heart disease, stroke) among women 50 through 59 years. Moreover, the risks from conjugated equine estrogens plus medroxyprogesterone were primarily inherent to the intervention phase, and both the risks and benefits were ultimately ephemeral throughout the post-intervention period.

In 2017, the WHI clinical studies [15] reported that there were 7,489 deaths throughout the treatment and surveillance periods; all-cause mortality was 27.1% for the women who underwent HRT vs. 27.6% in the placebo group (i.e., neither estrogen-alone nor in combination with medroxyprogesterone acetate was associated with an increased risk of cancer mortality). Accordingly, the North American Menopause Society revised its guidelines [19]; HRT was recommended for women who were younger than 60 or within 10 years of menopause, especially if they were at higher risk for bone loss or fracture.

A prolonged review of the WHI trials in 2019 suggested that estrogen-alone had a countervailing effect on breast cancer incidence, compared to the increased risk of breast cancer from estrogen/progestin therapy [14]. There was a 23% reduction in breast cancer for the postmenopausal woman who received estrogen therapy-alone, whereas the risk of breast cancer and breast cancer-related death was elevated by 29% for the women treated with estrogen/progestin, an effect that transcended 10-years of discontinued use.

U.K. HRT STUDIES

Despite the findings from the 2019 WHI study, an epidemiological study conducted in the U.K. reported that of the 108,647 postmenopausal subjects who developed breast cancer, 51% had been treated with HRT [5]. Interestingly, the elevated risk encompassed all types of HRT (vaginal estrogens excepted), particularly combined estrogen/progestin. The increased risk from estrogen/progesterone was evident for patients on therapy for 1–4 years, with a two-fold risk during years 5–14, particularly in women who ultimately developed estrogen receptor-positive breast cancer.

When considering the specific risks according to age, women who used HRT for 5 years, commencing at age 50 years, exhibited a significant increase in risk for breast cancer at ages 50–69 years (half of the elevated risk was attributed during the first 5 years of current HRT use and the other half was ascribed to the subsequent 15 years of prior use) [5]; this represents an absolute increase of approximately 2% for women undergoing estrogen/progesterone. Additionally, the corresponding risks with 10 years of use starting at age 50 years would be nearly two-fold.

In a subsequently published U.K. nested-control study, the researchers compared the impact of HRT on 98,611 breast cancer patients, ages 50–79, to 457,498 female control subjects [20]. Overall, HRT use was associated with an increased risk of breast cancer (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.19 to 1.23). Intriguingly, the elevated risk was attributed to both estrogen and progesterone (OR, 1.26; 95% CI, 1.24 to 1.29) and estrogen-only therapy (OR, 1.06; 95% CI, 1.03 to 1.10). They also reported that the associated risk
of breast cancer increased with advanced age, potentially attributed to relatively longer HRT use. Moreover, the association between HRT use and breast cancer progressively diminished with increasing years of HRT cessation.

**NON-HORMONAL OPTIONS**

In accordance with the numerous reported toxicities associated with HRT, women are persistently inquiring about medical alternatives to HRT in endeavoring to attenuate their menopausal symptoms. Neurotransmitter modulators, namely selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, fluoxetine) have been considered viable alternatives to hormone therapy [21-23]. Gabapentin, an anticonvulsant, and clonidine, an antihypertensive, have also been utilized to mitigate the frequency and severity of menopause-associated vasomotor symptoms by approximately 70% [24,25]; however, the precise mechanism of action inherent in these medications that attenuates patient symptoms remains indeterminate [23]. Soy and herbs have additionally conferred a reported beneficial effect in managing menopausal symptoms [26]. Please refer to Table 1 for a list of nonhormonal agents used as therapy for hot flashes [27-33].

**CONCLUSION**

HRT was routinely used in the 1990’s to attenuate menopausal symptoms and currently, greater than 40% of women in the United States are prescribed this treatment [34]. Moreover, HRT reduces symptoms by 75% in the management of vulvovaginal atrophy, a urogenital condition that occurs in approximately 40% of postmenopausal breast cancer patients following treatment [35]. The combined results from the aforesaid HRT trials are varied, and thus, confound an unequivocal approach to treating menopausal symptoms. Conversely, when endeavoring to assess the risks associated with HRT, we recognize the disadvantages of untreated vasomotor symptoms, which can impair quality of life and diminish work productivity [36]. Perhaps, before initiating HRT, the physician and patient should thoughtfully engage in discourse that incorporates the individual’s clinical symptoms and attendant risk profile.

**ACKNOWLEDGMENTS**

This study was supported by the Women’s Cancer Research Foundation, Joan and Len Rullo, in memory of Elizabeth Johnson, and Susan Berg.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33.
2. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237: 474-82.
3. Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 2018; 132: 111-5.
4. Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MPF, Martins RIL, et al. Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of
potential benefits and safety. Rev Assoc Med Bras (1992) 2020; 66: 1134-8.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159-68.
6. Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol 2014; 142: 16-29.
7. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
8. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
9. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
10. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progesterin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
11. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Maigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 1558-68.
12. Hilton HN, Clarke CL. Impact of progesterone on stem/progenitor cells in the human breast. J Mammary Gland Biol Neoplasia 2015; 20: 27-37.
13. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JE; Longcope C, et al. Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-26.
14. Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick M, Pan K, et al. Abstract GSS-00. Long-term influence of estrogen plus progesterin and estrogen alone use on breast cancer incidence: the Women’s Health Initiative randomized trials. Cancer Res 2020; 80(4 Suppl): GSS-00.
15. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 2017; 318: 927-38.
16. Ness J, Aronow WS, Newkirk E, McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women’s Health Initiative Trial. J Gerontol A Biol Sci Med Sci 2005; 60: 460-2.
17. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-4.
18. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-68.
19. The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24: 728-53.
20. Vinogradova Y, Coupland C, Hippius-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020; 371: m3873.
21. Albertazzi P. A review of non-hormonal options for the relief of menopausal symptoms. Treat Endocrinol 2006; 5: 101-13.
22. Imai A, Matsunami K, Takagi H, Ichigo S. New generation non-hormonal management for hot flashes. Gynecol Endocrinol 2013; 29: 63-6.
23. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377-81.
24. Handley AP, Williams M. The efficacy and tolerability of SSRIs/ SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract 2015; 27: 54-61.
25. Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith DA, Pruthi S, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77: 1159-63.
26. Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016; 315: 2554-63.
27. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med 2010; 16: 36-44.
28. Goldberg RM, Loprinzi CL, OFallon JR, Veeder MH, Miser AW, Mailliard JA, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12: 155-8.
29. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella P, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578-83.
30. Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health 2015; 7: 615-24.
31. Burke GL, Legault C, Anthony M, Bland DR, Morgan TM, Naughton MJ, et al. Soy protein and isoflavone effects on vaso-
motor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study. Menopause 2003; 10: 147-53.
32. Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study. Ann Oncol 2007; 18: 689-93.
33. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101: 337-45.
34. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-9.
35. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010; 19: 425-32.
36. Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause 2015; 22: 260-6.